Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.69 |
| ▸ | CDC14B | O60729 | 2/20 | 0.58 |
| ▸ | CDC14A | Q9UNH5 | 2/20 | 0.58 |
| ▸ | ACP3 | P15309 | 3/20 | 0.57 |
| ▸ | PGK1 | P00558 | 5/20 | 0.53 |
| ▸ | PGK2 | P07205 | 5/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10860781 | 0.81 | ACP3 (0.57) | PTPRCCDC14BCDC14AACP3PGK1 | |
| SCHEMBL3745971 | 0.79 | PTPRC (0.54) | PTPRCCDC14BCDC14APGK1PGK2 | |
| SCHEMBL8376250 | 0.75 | KDM4E (0.46) | PTPRCACP3KDM4EMEN1KMT2A | |
| SCHEMBL8376253 | 0.75 | HSD17B10 (0.47) | PTPRCACP3KDM4EMEN1KMT2A | |
| SCHEMBL3346090 | 0.75 | ACP3 (0.61) | PTPRCCDC14BCDC14AACP3PGK1 | |
| SCHEMBL29599325 | 0.74 | KDM4E (0.53) | ACP3KDM4EMEN1KMT2A | |
| SCHEMBL1161290 | 0.74 | KDM4E (0.53) | ACP3KDM4EMEN1KMT2A | |
| SCHEMBL8185296 | 0.73 | KDM4E (0.49) | PTPRCACP3KDM4EMEN1KMT2A | |
| SCHEMBL30707929 | 0.73 | KDM4E (0.49) | PTPRCACP3KDM4EMEN1KMT2A | |
| SCHEMBL8938009 | 0.73 | ACP3 (1.00) | PTPRCCDC14BCDC14AACP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120014911-A1 | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2012-01-19 | — | — | US | claimed |
| WO-2010080992-A1 | REGULATORS OF THE INTERFERON-ALPHA RECEPTOR 1 (IFNAR1) CHAIN OF THE INTERFERON RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-15 | — | — | WO | claimed |
| US-20120014911-A1 | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2012-01-19 | — | — | US | disclosed |
| WO-2010080992-A1 | REGULATORS OF THE INTERFERON-ALPHA RECEPTOR 1 (IFNAR1) CHAIN OF THE INTERFERON RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20060241020-A1 | Protein tyrosine phosphatase inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. | 2006-10-26 | — | — | US | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |